Chapter 15 & 16 - Liver, Gall bladder, Biliary Tract Flashcards
Liver
Organ found in vertebrates
Detoxifies various metabolites, synthesizes proteins, and produces biochemical necessary for digestion and growth
Located in upper right quadrant of the abdomen, below the diaphragm
Bilirubin
Brownish-yellow pigment secreted by the liver
Produced in bone marrow cells and liver as the end product of red-blood-cell (hemoglobin) breakdown
Amount of bilirubin manufactured relates directly to quantity of blood cells destroyed
About 0.5 to 2 grams produced daily
Unconjugated Bilirubin (Indirect Bilirubin)
Fat-soluble form of bilirubin, formed during the initial chemical breakdown of hemoglobin
While being transported in blood, it is mostly bound to albumin (binding affinity for albumin to bilirubin is extremely high, and under ideal conditions, no free [non-albumin bound] unconjugated bilirubin is seen in the plasma)
Conjugated Bilirubin (Direct Bilirubin)
When albumin-unconjugated bilirubin complex reaches the liver, sugars are attached to the unconjugated bilirubin to form water soluble conjugated bilirubin (direct bilirubin)
Then excreted in the bile and passes from the liver to the small intestines
(water-soluble)
Jaundice (hyperbilirubinemia)
Yellow discoloration of skin and sclerae occurring at a serum bilirubin of 2.0 mg/dl (normal is < 1.2)
Pathophysiology of Jaundice
Hemolytic anemia - excess production of bilirubin
Drug interference - Reduced hepatocellular uptake
Newborn jaundice, viral hepatitis - Impaired conjugation
Drug-induced damage, viral hepatitis - Decreased hepatic excretion of bile
Intrahepatic or extrahepatic bile duct damage, common duct obstruction by gallstones - Impaired bile flow
Hepatic Failure
Inability of the liver to perform its normal functions, life-threatening condition; urgent medical care
Acute or chronic (cirrhosis)
Recently, a 3rd form of liver failure known as acute-on-chronic liver failure (ACLF) is increasingly being recognized
Clinical Consequences: 80-90% of hepatic function lost (Jaundice, Hypoalbuminemia, Coagulopathy, Encephalopathy)
Acute Liver Failures
Rapid development of hepatocellular dysfunction, specifically coagulopathy and mental status changes (encephalopathy) in a patient w/out known prior liver disease
Usually drug-related or fulminant (fast and strong) viral hepatitis
Resulting in massive hepatic necrosis
Chronic Liver Failure
End point of chronic liver injury
Causes of cirrhosis: alcoholism, chronic hepatitis B or C, autoimmune hepatitis, hereditary and metabolic causes, metabolic derangements
Acute on chronic Liver Failure
occurs when a patient w/ chronic liver disease develops features of liver failure, underlying precipitating causes include: alcohol misuse, infection
Hepatic Encephalopathy
Loss of brain function as a result of failure in the removal of toxins from the blood due to liver damage, inc blood ammonia levels, liver flap
Symptoms: jaundice, must or sweet breath odor, problems in mvmt w/ abnormal tendon reflexes, altered loss of consciousness, changes in moods, personality changes
Diagnosis: Complete blood count, liver function test, CT Scan
Cirrhosis of Liver
Degenerative disease of the liver resulting in scarring and liver failure, asymptomatic until advanced stages
Causes: alcoholic liver disease: 60-70%, viral hepatitis: 10%, Biliary tract diseases: 5-10%
Symptoms: weakness, fatigue, muscle cramps, weight loss, nausea, vomiting, upper abdominal pain
Clinical features: anorexia, debilitation, abdominal swelling due to ascites
Classification: best system based upon etiology, fibrosis and conversion of liver architecture into structurally abnormal nodules
Macronodular - larger nodules (greater than 3 mm)
Micronodular - usually alcoholism, obesity, diabetes mellitus
Causes of Death - progressive hepatic failure, portal hypertension w/ esophageal bleeding, hepatocellular carcinoma
Portal Hypertension
Increase in the blood pressure within a system of veins called the portal venous system
Cirrhosis accounts for most cases of intrahepatic portal hypertension
Complications: Ascites, Portosystemic shunts (esophagogastric varices, hemorrhoidal varices, periumbilical and abdominal wall collaterals), Splenomegaly (congestive)
Hepatitis A
Vaccine-preventable liver infection caused by HAV
Found in the stool and blood of people who are infected
Highly contagious
HAV can live outside the body for months
HAV is killed when exposed to temperatures of >185 degrees F for 1 min
Incubation Period: range: 15-50 days
*Does not become a chronic, long-term infection
Transmission: Close person-to-person contact w/ an infected person, sex contact w/ infected, ingestion of contaminated food or water
At risk individuals: international travelers, ppl who anticipate close personal contact w/ international adoptee
Signs & Symptoms: Fever, fatigue, loss appetite, nausea, vomiting, abdominal pain, dark urine, diarrhea, jaundice
symptoms last less than 2 months, 10-15% of symptomatic persons have prolonged or relapsing disease for up to 6 mo
Diagnosis: Antibody to hep a virus, nucleic acid amplification test
Prevention: Vaccination, Immune globulin, Good hand hygiene
Vaccination: Children (all aged 12-23 mo, unvaccinated children and adolescents aged 2-18 yrs)
Hepatitis B
Vaccine-preventable liver infection caused by HBV, spreads when blood, semen, or other body fluids from a person infected w/ virus
Incubation Period: average of 90 days (range: 60-150 days)
Transmission: sexual contact, sharing syringes, other drug-injection equipment, mother to baby
Virus can live on objects for 7 days or more
Symptoms: last several weeks, persist up to 6 mo, pain in area of liver or abdominal pain, fever, loss of appetite, extreme fatigue and weakness, itching, dark urine, joint pain, jaundice
Infections: acute or chronic
Diagnosis: Hep B surface antigen, Hep B surface antibody, total hep B core antibody
Treatment: Acute infection - less than 6 mo, Chronic infection - more than 6 mo
Meds: Antivirals - stop replication of virus, Immunomodulators - reduces viral load by preventing replication of viruses
Vaccination schedules: 3 intramuscular injections, second and third doses administered at 1 and 6 mo